ClinicalTrials.govpublic full text
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
end stage kidney disease (eskd), high-sensitivity c-reactive protein, high-density lipoprotein cholesterol, interleukin-6, humanized monoclonal antibody, atherosclerotic cardiovascular disease, diabetes mellitus, systemic inflammation, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 858998
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.